Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neutrophil Elastase Inhibition as Adjunctive Therapy to Improve Glucometabolic Variables in Overweight and Obese, Insulin-Resistant Type 2 Diabetic Patients

NCT02597101 is registered in ClinicalTrials.gov with Nick Giannoukakis, PhD as lead sponsor.

NCT NCT02597101
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02597101 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neutrophil Elastase Inhibition as Adjunctive Therapy to Improve Glucometabolic Variables in Overweight and Obese, Insulin-Resistant Type 2 Diabetic Patients
Lead sponsor
Nick Giannoukakis, PhD
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2015
Completion date
June 15, 2019
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

insulin resistance, type 2 diabetes mellitus